IOVA News and Press, Iovance Biotherapeutics Inc. From 10/19/23

2023-10-19 14:35:36 ET Summary Iovance Biotherapeutics' lifileucel, a tumor infiltrating lymphocyte product, is under FDA review for the treatment of advanced melanoma. The FDA decision on the biologics license application for lifileucel has been delayed until February 24, 2024. ...

SAN CARLOS, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the publication of...

SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced poster presentati...

2023-09-18 22:43:32 ET Summary Iovance Biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust financials with a cash runway of 13.1 months. Insider buying and strategic ATC investments indicate market confidence; however, clinician adoption a...

2023-09-18 11:00:05 ET More on Iovance Biotherapeutics Seeking Alpha’s Quant Rating on Iovance Biotherapeutics Historical earnings data for Iovance Biotherapeutics Financial information for Iovance Biotherapeutics Iovance Biotherapeutics: Why The Stock...

2023-09-18 08:16:42 ET SeqLL  ( NASDAQ: SQL ) +70% . TradeUP Acquisition  ( UPTD ) +11% . Tian Ruixiang Holdings ( TIRX ) +11% . Virios Therapeutics ( VIRI ) +9% terminates at-the-market sales agreement. Village Farms Inter...

2023-09-15 16:20:46 ET Iovance Biotherapeutics (NASDAQ: IOVA) is being shifted to the fast track in its current approval process for an investigational drug. On news that the Food and Drug Administration (FDA) is willing to make the process faster, enthusiastic investors traded the ...

2023-09-15 13:18:16 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) stock price defied gravity on Friday as investors cheered the latest FDA update about its drug. The shares jumped by more than 15% even as the Nasdaq 100 and S&P 500 indices retreated. This jump pushed its market ca...

2023-09-15 13:11:06 ET Gainers: MSP Recovery ( LIFW ) +199% . AERWINS Technologies ( AWIN ) +104% . AgriFORCE Growing Systems Ltd. ( AGRI ) +40% . RayzeBio ( RYZB ) +37% . Novonix Limited ( NVX ) +31% . Greenland Technologies...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is one today's most active stocks by volume. So far today, approximately 30.7M shares of Iovance Biotherapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.19M shares. Iovance Biotherapeutics, Inc., a clinical-stage biot...